Cytox And Affymetrix Form Strategic Partnership To Develop And Commercialize Blood-Based Genetic Assay For Alzheimer’s Disease Risk Assessment
20 July 2015: Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment…
read more
Cytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.